Level C· Early human research exploring benefitsCohort StudyPubMedOpen access

Adipose stem cells from patients with Crohn's disease show a distinctive DNA methylation pattern.

Serena C., Millan M., Ejarque M., Saera-Vila A., Maymó-Masip E., Núñez-Roa C.

Cohort Study with a reported sample of 7 on Autoimmune Research, published in Clin Epigenetics (2020) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Cohort Study
Journal
Clin Epigenetics (2020)
Country
Germany
Reported sample size
7
Source database
PubMed
PMID
32252817
PMCID
PMC7137346
DOI
10.1186/s13148-020-00843-3
Citations
26

Abstract (original English)

Background Crohn's disease (CD) is characterized by persistent inflammation and ulceration of the small or large bowel, and expansion of mesenteric adipose tissue, termed creeping fat (CF). We previously demonstrated that human adipose-derived stem cells (hASCs) from CF of patients with CD exhibit dysfunctional phenotypes, including a pro-inflammatory profile, high phagocytic capacity, and weak immunosuppressive properties. Importantly, these phenotypes persist in patients in remission and are found in all adipose depots explored including subcutaneous fat. We hypothesized that changes in hASCs are a consequence of epigenetic modifications. Methods We applied epigenome-wide profiling with a methylation array (Illumina EPIC/850k array) and gene expression analysis to explore the impact of CD on the methylation signature of hASCs isolated from the subcutaneous fat of patients with CD and healthy controls (n = 7 and 5, respectively; cohort I). Differentially methylated positions (p value cutoff -4 and ten or more DMPs per gene) and regions (inclusion threshold 0.2, p value cutoff -2 and more than 2 DMRs per gene) were identified using dmpfinder and Bumphunter (minfi), respectively. Changes in the expression of differentially methylated genes in hASCs were validated in a second cohort (n = 10/10 inactive and active CD and 10 controls; including patients from cohort I) and also in p

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueCase-Control StudiesCell Culture TechniquesCrohn DiseaseDNA MethylationEpigenesis, GeneticEpigenomicsFemaleGene Expression ProfilingGene Expression Regulation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research